Navigation Links
Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines

Greffex, a leading genetic engineering company, with the world’s first universal vaccine platform delivered through the use of proprietary clean viral vectors, recently announced a key manufacturing agreement with FUJIFILM Diosynth Biotechnologies to produce its vaccine in the United States. Greffex’s platform is the world’s most successful gene therapy delivery vehicle (vector) with broad applications for delivering treatments including vaccines, immune suppression and gene therapy.

"We are delighted to be selected by Greffex as their CDMO (Contract Development & Manufacturing Organization) partner," said Gerry Farrell, chief operating officer, FDB Texas site. "FDB looks forward to our work together to bring these ground-breaking therapies to market to meet the critical need for global vaccines. "

John R. Price, Greffex Co-Chairman of the Board, President and CEO said “Greffex is excited to be working with FUJI Diosynth. This is a major step in our progression; helping to fulfill our vision of becoming an international Bio Pharmaceutical Company Headquartered in Texas creating innovative therapies to protect and heal mankind.”

In 2019, Greffex was awarded an $18.9 million contract from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. This award will enable Greffex to develop and exploit its GreVac(TM) Plug-And-Play Technology to expedite the production of vaccine candidates for biodefense and emerging infectious diseases to target infectious threats, whether natural or man-made.

Greffex, a leading genetic engineering company founded in 2005, has developed the world’s first universal vaccine platform that delivers unprecedented time-to-market, cost efficiency, efficacy and safety through the use of proprietary clean viral vectors. The company has 14 vaccines in its development portfolio, numerous gene therapies in development including Hemophilia A and Usher Syndrome, and immune tissue engineering aimed at overcoming transplant rejection.

Greffex is headquartered in Houston, Texas with laboratories in Aurora, Colorado.

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology technology :

1. DeepDyve Signs New Partnership Agreement with the Institute of Physics
2. New Vision Test Helps Detect Early Signs of Glaucoma
3. Aluflam Signs Deal To Automate Window & Door Manufacturing
4. EpiVax Signs First Commercial License for Tregitope Technology
5. RepliCels Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
6. Cousins Properties Signs 125,000 Square Foot Lease with Amgen at Corporate Center in Tampa, FL
7. New Synergy Collection By StemCutis Rejuvenates Skin And Repairs Signs Of Aging
8. Former Allergan Chief David Pyott Signs on as Special Advisor to Sienna Biopharmaceuticals
9. RepliCel Signs Two Key Service Partnerships for Final Prototype Manufacturing and Testing of its Dermal Injector
10. TRIANNI Signs Licensing Agreement for Transgenic Mouse Platform Use with Janssen
11. THC Signs Definitive Agreement to Purchase Clone Shipper
Post Your Comments:
(Date:7/1/2020)... WESTMINSTER, Colo. (PRWEB) , ... ... ... providers of expert tissue data insights, today announced that the launch of ... PD-L1 results along with data about the tumor microenvironment (TME). , “Flagship’s ...
(Date:6/28/2020)... JOSE, Calif. (PRWEB) , ... June 25, 2020 ... ... globe, researchers are racing to develop a vaccine or drug treatment. In an ... Recursion has publicly released the world’s largest imaging dataset portraying therapeutic ...
(Date:6/28/2020)... ... June 26, 2020 , ... The ... today announced its strong opposition to the recently introduced bicameral Facial Recognition ... ban on most federal use of nearly all biometric and related image analytics ...
(Date:6/23/2020)... ... June 23, 2020 , ... DeCurtis Corporation, the ... today that Derek Fournier has been appointed CEO and President. Founder and former ... immediately. , “DeCurtis Corporation has been on an incredible journey for the ...
Breaking Biology Technology:
(Date:6/25/2020)... Mass. (PRWEB) , ... June 24, 2020 , ... ... of cloud-based enterprise software and software-driven clinical data services that accelerate drug development, ... for low-dose selinexor, an XPO1 inhibitor, in hospitalized patients with severe COVID-19. This ...
(Date:6/23/2020)... ... 22, 2020 , ... The field of quantitation of large molecules or proteins ... this area. However, the use of mass spectrometry in this field has gained a ... “How do you choose which approach to use (LBA or MS)?” In many ...
(Date:6/19/2020)... ... ... The director of stem cell biotechnology company Asymmetrex , Dr. James L. ... have easier access to stem cell counting, they will soon make it a routine ... weekend in the U.S., Asymmetrex is offering free tissue stem cell counting at its ...
Breaking Biology News(10 mins):